Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADH5 | P11766 | 10/20 | 0.46 |
| ▸ | DHODH | Q02127 | 1/20 | 0.43 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | STING1 | Q86WV6 | 1/20 | 0.39 |
| ▸ | TBXAS1 | P24557 | 2/20 | 0.38 |
| ▸ | CNR2 | P34972 | 1/20 | 0.37 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.37 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.37 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20536624 | 0.82 | ADH5 (0.41) | ADH5DHODHCYP3A4BAZ2BSTING1 | |
| SCHEMBL30772941 | 0.82 | ADH5 (0.41) | ADH5DHODHCYP3A4BAZ2BSTING1 | |
| SCHEMBL22077986 | 0.82 | ADH5 (0.44) | ADH5DHODHPTPN11CYP3A4BAZ2B | |
| SCHEMBL22078072 | 0.81 | ADH5 (0.53) | ADH5CYP3A4BAZ2BHTTTBXAS1 | |
| SCHEMBL22078079 | 0.79 | ADH5 (0.40) | ADH5DHODHSTING1TBXAS1CNR2 | |
| SCHEMBL16126788 | 0.75 | CYP11B1 (0.53) | CYP3A4HTTENPP2MKNK1MKNK2 | |
| SCHEMBL22078076 | 0.75 | TBXAS1 (0.53) | ADH5CYP3A4BAZ2BTBXAS1 | |
| SCHEMBL22077255 | 0.75 | ESR1 (0.48) | ADH5CYP3A4BAZ2BTBXAS1 | |
| SCHEMBL22078064 | 0.74 | ADH5 (0.53) | ADH5DHODHCYP3A4BAZ2BHTT | |
| SCHEMBL22078070 | 0.74 | TBXAS1 (0.46) | CYP3A4HTTTBXAS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11655244-B2 | Carbazole compounds and methods of use thereof | GSNO THERAPEUTICS, INC. (US) | 2023-05-23 | — | — | US | disclosed |
| US-20200181129-A1 | CARBAZOLE COMPOUNDS AND METHODS OF USE THEREOF | GSNO THERAPEUTICS, INC. | 2020-06-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11655244-B2 | Carbazole compounds and methods of use thereof | GSR, CBR3, CBR1 | ADH5 93/4885DHODH 302/4885PTPN11 3157/4885 |
| US-20200181129-A1 | CARBAZOLE COMPOUNDS AND METHODS OF USE THEREOF | GSR, CBR3, CBR1 | ADH5 93/4885DHODH 302/4885PTPN11 3157/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.